Background. Endogenous resolution mechanisms that promote return to homeostasis are defective in cystic fibrosis (CF) leaving inflammation unrestrained with consequent loss of respiratory function, disability, and premature death of patients. Resolvin (Rv) D1 is and endogenous pro-resolution mediator that has entered clinical trials for the treatment of inflammatory diseases. Therefore, its therapeutic potential in CF is of wide interest.

Hypothesis and Objectives. Overarching hypotheses tested in this project are that RvD1 represents a potent therapeutic candidate for limiting lung inflammation and enhancing resolution of P. aeruginosa infection in CF. Main objectives are to determine, in preclinical models of CF, if RvD1 a) dampens lung inflammation and damage, b) promotes resolution and clearance of bacterial infection